Oliver Weingärtner: What Can Real-World Data Teach Us about Long-Term Treatment Persistence in CP?
Oliver Weingärtner, Professor of Medicine at Friedrich-Schiller University Jena, shared a post on LinkedIn about a recent article by Wolfgang Koenig et al., published in Clinical Research in Cardiology, adding:
“Another Alarming Gap in Cardiovascular Care
What can real-world data teach us about long-term treatment persistence in cardiovascular prevention?
Cardiovascular disease remains the leading cause of death in Germany.
While effective strategies exist to lower LDL cholesterol and reduce cardiovascular risk, a major challenge remains: many patients do not stay on treatment over the long term.
A retrospective cohort study analyzed real-world data from nearly 900,000 patients over 36 months.
The findings highlight an important gap in the patient journey and raise critical questions about how we support patients beyond.
The Persistence Challenge
- A substantial proportion of patients discontinued treatment within the first year.
- Long-term persistence remained low over the 36-month follow-up period.
- Women consistently demonstrated lower persistence rates than men.
The Silver Lining
Among patients who remained on therapy, adherence was generally high, suggesting that once patients stay engaged with treatment, they are often able to follow their prescribed regimen successfully.
The Bigger Picture
The challenge is not only identifying patients at risk and initiating appropriate management.
It is also ensuring ongoing support throughout the patient journey to help patients remain engaged with long-term cardiovascular risk reduction strategies.
Improving persistence may require a combination of patient education, shared decision-making, regular follow-up, and healthcare system interventions that address barriers to long-term treatment.
Every step in the patient journey matters.
From risk identification and diagnosis to long-term management and follow-up, helping patients stay engaged in their care remains a key opportunity to improve cardiovascular outcomes.
How can we better support patients throughout their cardiovascular prevention journey to improve long-term treatment persistence?”
Title: Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany
Authors: Wolfgang Koenig, Elke S. Lorenz, Lea Beier, Ioanna Gouni-Berthold
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 19, 2026, 10:34Nawsherwan Mohammad: ASH 2026 Guidelines Redefine How We Detect Iron Deficiency
-
Sep 19, 2026, 10:21Upcoming Podcast on Thalassaemia with The Lancet Haematology
-
Sep 19, 2026, 10:20Steve Helm: Cardiology and Anticoagulation Pharmacist Role Opens Near NYC
-
Sep 19, 2026, 10:12Omid Seidizadeh: A Great Pleasure to Speak on vWD at the 59th NordCoag Congress
-
Sep 19, 2026, 10:08Carsten Hansen: What Happens During a Sickle Cell Crisis?
-
Sep 19, 2026, 10:05Alan Nurden: Thyroid Hormones as Regulators of Acute Platelet Release
-
Sep 19, 2026, 09:55Ammar Alsughayir: When Transfusion Safety Becomes a Lifelong Commitment
-
Sep 19, 2026, 09:53Dilini Christina Ranasinghe: Exploring Red Cell Exchange in Sickle Cell Disease
-
Sep 19, 2026, 09:48Kanchal Mahesh: A First Step Into the World of Research